The United Kingdom has consistently been a source of globally influential innovation. This is due to strong research institutions, an active venture ecosystem, and deep technical expertise across multiple industries. A new generation of innovative startups is now translating this foundation into commercially relevant technologies. They are supported by patent portfolios that signal both technological leadership and long-term strategic intent. To identify the UK startups that are leading this innovation wave, LexisNexis Intellectual Property Solutions conducted a patent analytics study. We focused on the strength and quality of patent portfolios, rather than filing volume alone. The analysis highlights the companies whose intellectual property positions them to exert outsized influence in their respective technology domains.
The analysis began with a comprehensive review of private, active, and for-profit companies headquartered in the United Kingdom and founded since 2010. Public companies, subsidiaries of larger corporate groups, government-controlled entities, academic institutions, and investment firms were excluded. This was to ensure that the ranking reflects independent, early-stage innovators. Raw data was pulled from Crunchbase including 86,255 company records. Patent holding companies were mapped to the LexisNexis® PatentSight+™ analytics platform for conducting the analysis. Innovation strength was assessed using the Patent Asset Index, a metric that combines portfolio size with Technology Relevance and geographic Market Coverage. Technology Relevance captures how frequently a patent is cited by subsequent patents, normalized for technology field, patent age, and jurisdiction-specific citation behavior. Market Coverage reflects the economic size of the jurisdictions in which patent protection is sought. Together, these indicators enable a more meaningful comparison of innovation strength across companies of different sizes and sectors.
The resulting top 10 ranking reflects the breadth of the UK innovation ecosystem. The most innovative startups span automotive and mobility technologies, video compression, medical robotics, advanced materials, clean energy, semiconductors, biotechnology, and consumer technologies.
What unites these companies is not scale but focus. Many operate in technically complex domains where a relatively small number of high-impact patents can underpin platform technologies with broad downstream applicability. While based in the UK, the patents held by these companies show global influence, as major corporates cite them as prior art. For example, Envisics is cited by Samsung, V-Nova by Huawei, and CMR Surgical by Johnson & Johnson.
Innovative startups portfolio strength and portfolio size comparison
A major driver for innovation in the UK is the research taking place at the country’s top tier universities, as highlighted by the number of companies on the UK Most Innovative Startups list that were spun out of major universities. Among those companies are Oxford PV (University of Oxford), Mission Therapeutics (University of Cambridge), Paragraf (University of Cambridge), and Nuclera (University of Cambridge). In addition, CMR Surgical came out of the Cambridge ecosystem, although not directly from the university, and another company, Deep Render (Imperial College London), would have made the list at number 10 if it had it not been acquired by InterDigital.
Discover which patents in your portfolio drive the most impact. Talk to an expert.
Envisics is a globally renowned dynamic holography pioneer, focused on developing holographic technologies for augmented reality head-up displays (AR-HUDs) and automotive sensor systems. ENVISICS® branded technology harnesses the power of holography and laser-based light sources to provide the highest possible image quality. The advancement of ENVISICS® branded technology has the opportunity to transform automotive displays and revolutionize the in-car experience. In partnership with the world’s leading automakers and tier-one suppliers, Envisics is making the future of holographic technology a reality for smarter and safer vehicles. V-Nova is a deep technology company committed to unlocking higher quality digital experiences at scale. The Company’s technologies, based on the innovative use of AI and parallel processing, improve data, video, imaging, point cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 1300 international patents, along with a range of software products and solutions.CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot. CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.Oxford PV is a pioneer and leader in the field of perovskite PV technology. The company was established in 2010, as a spin-out from the University of Oxford. It focuses on developing and commercialising next‑generation tandem solar technology. Oxford PV operates a research and development site in Oxford, UK, alongside an integrated production line near Berlin, Germany, enabling the accelerated transfer of its technology into industrial‑scale manufacturing of perovskite‑on‑silicon tandem solar cells and modules.Octopus Energy is a global clean energy and technology business, driving the affordable, green energy system of the future. Under its own retail brand, Octopus delivers world-class customer service and cutting-edge energy products to 11 million households globally. The company is driving the electrification of heat and transport through smart tariffs and innovative clean tech, with operations spanning 27 countries and the entire energy value chain. It operates a £7 billion renewables portfolio as well as thriving EV leasing, heat pump, and solar businesses.Mission Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics that promote mitophagy, the quality control process cells use to remove dysfunctional mitochondria, thereby safeguarding their health and function. Effective mitophagy is particularly important for protecting the health of cells and organs that are highly energy consuming such as brain, heart, and kidney.Paragraf was founded in 2015 and is pioneering the development and commercial adoption of graphene-based electronic devices using industry-standard semiconductor processes. With lines of graphene Hall sensors (GHS) and graphene field effect transistors (GFET) already in production, and other advanced semiconductor devices in development, Paragraf’s proprietary graphene growth process is unlocking the full potential of this remarkable material.Nuclera provides rapid, easy access to high-quality, functional proteins, accelerating drug discovery. We make proteins accessible through eProtein Discovery. Through our technology, we accelerate breakthrough improvements in human health and empower life science researchers with easy access to target proteins.Refilla by AYR is a passionate London-based team of designers, engineers and software specialists with one mission: to make vaping better. Refilla is committed to making vaping more sustainable with a refillable, rechargeable product; reusable components; and reduced waste.Low Carbon creates large-scale renewable energy to fight climate change. Low Carbon invests in, develops, and operates solar, wind, energy storage, and energy from waste projects across the UK, Europe, and North America. It is contributing to the world’s move to 100% renewable energy by creating and operating 20GW of new capacity, and it has more than 16GW in new renewables in development right now across the globe.
Portfolio strength across technology clusters
To explore how a data-driven approach could benefit your own portfolio, speak with our team about a customized assessment.
When benchmarked against mature corporate patent holders in their respective fields, the scale difference is clear. Even the strongest startup portfolios represent only a fraction of the total patent strength held by global incumbents. However, this comparison also highlights a critical insight: average patent quality among the top UK innovative startups often matches or exceeds that of established players. While incumbents benefit from breadth, start-ups frequently outperform in narrowly defined, high-impact technologies. Deep Render would have made the list of most innovative UK startups at number 10 if had it not been acquired by InterDigital, on October 30, 2025. The example shows how Deep Render, who came out of Imperial College London, was positioned in their core technology video and image compression covered in H04N against established tech players.
Quality versus quantity positionings of players in H04N – Pictorial communication
Their compact but potent IP footprint positioned Deep Render as attractive partners, technology suppliers, or acquisition targets for larger organizations seeking targeted innovation rather than broad portfolio expansion. When analyzing who was building on Deep Render as prior art, the acquisition by InterDigital doesn’t come as a surprise.
According to Financial Times, CMR Surgical has put itself for sale, seeking a $4 billion valuation. Recently they achieved another milestone securing the CE Mark approval for their Versius surgical robotic system. Applying the same citation analysis on a quantitative and qualitative level returns a set of known players in the field of medical technology. This is spearheaded by Johnson & Johnson most actively and most impactful citing CMR Surgical’s portfolio. In addition, companies form industrial automation like Fanuc or Kawasaki Heavy Industry also build on CMR Surgical’s robotics expertise.
Development of active portfolios citing CMR Surgical
Beyond citation-based indicators of patent quality, additional insight can be gained by examining how the patent portfolios of relevant players are concentrated across specific IPC and CPC technology groups within A61B, where strategic emphasis on particular surgical modalities becomes visible.
Concentration of patent strength of selected players in A61B – Diagnosis; Surgery; Identification
Do you want to identify upcoming startups in your core technology? Speak with an expert.
The chart illustrates that within the IPC and CPC class A61B, CMR Surgical shows a pronounced concentration in A61B 34. This covers computer-aided surgery and robotic or manipulator-based surgical systems. The focus closely mirrors that of Intuitive Surgical. Their long-standing leadership in robotic surgery has been built on a similarly concentrated patent position in this sub-class. The overlap highlights CMR Surgical as a technically coherent fit for any player seeking to expand or reinforce its footprint in computer-assisted surgery. Johnson & Johnson displays a comparatively lower relative emphasis in A61B 34. However, it continues to advance its position in medical robotics. They have done this through the development of its Ottava robotic surgical system, signaling strategic intent despite a broader and more diversified patent base. Medtronic, meanwhile, recently announced its intent to acquire CathWorks. This underlines its preference for targeted acquisitions to strengthen data-driven and technology-enabled intervention capabilities. This move raises the question of whether an additional acquisition in the surgical robotics space within a short timeframe would be strategically or financially realistic.
Patent analytics cannot predict the future. They can, however, provide deep insights into technological fit, strategic alignment, and the relative maturity of innovation portfolios. This analysis underscores the value of patent analytics as a tool for identifying innovation leadership at an early stage. By focusing on quality-adjusted metrics such as the Patent Asset Index, it becomes possible to distinguish between incremental patenting activity and genuinely influential technological development. For IP professionals, investors, and corporate strategy teams, such insights support more informed decision making, from partnership scouting and M&A evaluation to long-term portfolio planning.
What efficiencies are hidden within your patent portfolio? Discover how data-driven patent portfolio management can strengthen your IP position.
